About the Company
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the discovery, development, and delivery of the treatment of neurological diseases to patients worldwide. Biogen operates in Argentina, Brazil, Canada, China, France, Germany, Hungary, India, Italy, Japan, Mexico, Netherlands, Poland, Sweden, and Switzerland.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on BIOGEN INC.
Biogen Lifts Outlook As Rare Disease And Alzheimer's Drug Sales Accelerate
Biogen Inc. (NASDAQ:BIIB) reported on Thursday that the second quarter of 2025 adjusted earnings per share were $5.47, up 4% year over year, beating the analyst consensus of $4.06. The company ...
Biogen sees potential in combining Alzheimer’s and obesity drugs
Cambridge-based Biogen is looking to the growth of its Alzheimer’s drug Leqembi to offset the decline of its multiple ...
Biogen Inc. stock underperforms Monday when compared to competitors
Biogen Inc. closed 34.53% below its 52-week high of $207.59, which the company achieved on August 21st.
Biogen Inc. stock outperforms competitors on strong trading day
Biogen Inc. closed 33.11% below its 52-week high of $207.59, which the company reached on August 21st.
Biogen’s Innovative Study on Litifilimab Delivery: Market Implications and Study Insights
((BIIB)), Biogen ((CC:HTER)) announced an update on their ongoing clinical study.Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, ...
Biogen’s Phase 3 Study on Felzartamab: A Potential Game-Changer for IgA Nephropathy
Biogen (($CC:HTER)) announced an update on their ongoing clinical study. Biogen Inc. (BIIB) is currently conducting a Phase ...
Biogen plans $1B in cost-savings as CEO steps down
After more than five years at the helm of embattled Biogen Inc., Michel Vounatsos is stepping down as the company plans "additional cost-reduction and productivity measures" to save about $1 billion.
Biogen Agrees to Pay $900 Million Over Alleged Improper Physician ...
Biogen Inc. agreed to pay $900 million to settle allegations that it paid kickbacks to doctors to induce them to prescribe the company’s drugs, the Justice Department said Monday.
Biogen's 2022 forecast well below Street view on Alzheimer's drug ...
Biogen Inc on Thursday forecast 2022 profit well below Wall Street estimates as sales of its new Alzheimer's disease drug stall, and said it was considering deals of all sizes.
Biogen to start shipping Alzheimer's drug in about two weeks
Biogen Inc (BIIB.O) said on Tuesday it expects to begin shipping its newly approved Alzheimer's drug Aduhelm in about two weeks and has prepared more than 900 healthcare centers for the ...
Similar Companies
Loading the latest forecasts...